Gland Pharma Share Price

Gland Pharma Share Price

  • 2,267.80-20.70 (-0.91%)
  • Closed
  • As On: 10 Jun, 2026, 03:52 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Try ETMarkets GPTNEW
Open2,299.00
High2,341.50
Low2,250.00
Prev Close2,288.50
Volume3,20,379
VWAP(₹)2,300.30

Key Metrics

PE Ratio(x)36.37
EPS - TTM(₹)62.35
MCap(₹ Cr.)37,363.46
MCap Rank18
PB Ratio(x)3.64
Div Yield(%)-
Face Value(₹)1.00
52W High(₹)2,396.00
52W Low(₹)1,573.60
MCap/Sales4.35
Beta(1 Month)-
BV/Share(₹)628.68

Gland Pharma share price insights

Rank 364 - ET 5002025 ranking

  • Intraday fact check

    In the last 5 years, only 1.53 % trading sessions saw intraday declines higher than 5 % .

  • Employee & Interest Expense

    Company has spent less than 1% of its operating revenues towards interest expenses and 25.33% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

  • Candle Formations Yesterday

    Black Spinning Top was formed for Gland Pharma

  • Gland Pharma Share Price Update

    Gland Pharma Ltd. share price moved down by -0.91% from its previous close of Rs 2,288.50. Gland Pharma Ltd. stock last traded price is 2,267.80

    Share PriceValue
    Today/Current/Last2,267.80
    Previous Day2,288.50

Found Insights useful?

Gland Pharma Share Price Returns

1 Day-0.91%
1 Month19.08%
3 Months34.33%
1 Year36.23%
3 Years136.34%
5 Years-28.1%

Gland Pharma Share Recommendations

Mean recosCurrent
BUY

15 Analysts

Strong
SellSellHoldBuyStrong
Buy
Analyst Trends
RatingsCurrent1W Ago1M Ago3M Ago
Strong Buy7766
Buy3333
Hold2222
Sell2233
Strong Sell1111
# Analysts15151515
Recent Recos
  • Target₹1970
  • OrganizationMotilal Oswal Securities
  • BUY
  • Target₹2440
  • OrganizationMotilal Oswal Financial Services
  • BUY
  • Target₹2240
  • OrganizationMotilal Oswal Financial Services
  • BUY
View all Stock Recommendations

News & Analysis

View all Gland Pharma Share News & Announcements

Financials

  • Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
    Total Income1,758.541,571.041,563.151,468.941,442.55
    Total Income Growth (%)11.930.506.411.83-1.57
    Total Expenses1,392.481,279.301,238.911,173.161,120.42
    Total Expenses Growth (%)8.853.265.614.71-6.83
    EBIT366.06291.74324.24295.78322.12
    EBIT Growth (%)25.47-10.029.62-8.1822.53
    Profit after Tax (PAT)261.48183.68215.48186.54204.69
    PAT Growth (%)42.35-14.7615.51-8.8725.17
    EBIT Margin (%)20.8218.5720.7420.1422.33
    Net Profit Margin (%)14.8711.6913.7912.7014.19
    Basic EPS (₹)15.8711.1513.0811.3212.42
    Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
    Total Income1,237.721,156.741,093.581,074.071,075.85
    Total Income Growth (%)7.005.781.82-0.16-4.01
    Total Expenses824.76744.10723.76679.30663.41
    Total Expenses Growth (%)10.842.816.542.40-10.45
    EBIT412.96412.64369.82394.77412.44
    EBIT Growth (%)0.0811.58-6.32-4.288.54
    Profit after Tax (PAT)307.85302.00269.26290.00295.12
    PAT Growth (%)1.9412.16-7.15-1.744.76
    EBIT Margin (%)33.3635.6733.8236.7538.34
    Net Profit Margin (%)24.8726.1124.6227.0027.43
    Basic EPS (₹)18.6818.3316.3417.6017.91
    FY 2025FY 2024FY 2023FY 2022FY 2021
    Total Revenue5,830.115,834.963,865.064,624.653,597.65
    Total Revenue Growth (%)-0.0850.97-16.4228.5529.77
    Total Expenses4,767.454,702.422,754.023,006.092,262.84
    Total Expenses Growth (%)1.3870.75-8.3932.8527.16
    Profit after Tax (PAT)698.53772.46781.041,211.66996.96
    PAT Growth (%)-9.57-1.10-35.5421.5429.00
    Operating Profit Margin (%)19.6620.4530.8536.8938.64
    Net Profit Margin (%)12.4313.6321.5427.5328.79
    Basic EPS (₹)42.4046.9047.4473.8163.07
    FY 2025FY 2024FY 2023FY 2022FY 2021
    Total Revenue4,331.224,334.093,856.994,624.653,597.65
    Total Revenue Growth (%)-0.0712.37-16.6028.5529.77
    Total Expenses2,865.642,928.602,752.133,005.612,262.80
    Total Expenses Growth (%)-2.156.41-8.4332.8327.16
    Profit after Tax (PAT)1,089.751,043.33775.831,212.16997.01
    PAT Growth (%)4.4534.48-36.0021.5829.00
    Operating Profit Margin (%)36.1633.9130.7536.9038.64
    Net Profit Margin (%)26.4725.0321.4527.5428.79
    Basic EPS (₹)66.1563.3547.1273.8463.07

    All figures in Rs Cr, unless mentioned otherwise

    Insights

    • Employee & Interest Expense

      Company has spent less than 1% of its operating revenues towards interest expenses and 25.33% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
    View Details
  • AnnualFY 2025FY 2024FY 2023FY 2022FY 2021
    Total Assets11,224.9210,661.258,777.547,833.626,496.08
    Total Assets Growth (%)5.2921.4612.0520.5958.98
    Total Liabilities2,074.181,937.40818.81676.00592.84
    Total Liabilities Growth (%)7.06136.6121.1314.0334.80
    Total Equity9,150.748,723.847,958.727,157.625,903.24
    Total Equity Growth (%)4.899.6111.1921.2561.90
    Current Ratio (x)4.334.049.4610.0510.00
    Total Debt to Equity (x)0.030.040.000.000.00
    Contingent Liabilities184.34100.73128.46124.5374.70
    AnnualFY 2025FY 2024FY 2023FY 2022FY 2021
    Total Assets10,421.629,541.098,773.187,834.146,496.06
    Total Assets Growth (%)9.238.7511.9920.6058.98
    Total Liabilities666.52545.80819.88675.91592.77
    Total Liabilities Growth (%)22.12-33.4321.3014.0334.78
    Total Equity9,755.108,995.297,953.307,158.235,903.29
    Total Equity Growth (%)8.4513.1011.1121.2661.90
    Current Ratio (x)11.0111.049.4310.0410.00
    Total Debt to Equity (x)0.000.000.000.000.00
    Contingent Liabilities114.68100.73128.46124.53219.23

    All figures in Rs Cr, unless mentioned otherwise

    View Details
  • AnnualFY 2025FY 2024FY 2023FY 2022FY 2021
    Net Cash flow from Operating Activities914.73996.80363.97790.77604.93
    Net Cash used in Investing Activities1,704.74-1,756.911,208.19-1,002.62-1,524.00
    Net Cash flow from Financing Activities-433.48-799.4214.9234.901,238.46
    Net Cash Flow2,199.12-1,551.811,590.08-173.64322.97
    Closing Cash & Cash Equivalent2,556.21357.091,908.90318.82492.46
    Closing Cash & Cash Equivalent Growth (%)615.85-81.29498.74-35.26190.54
    Total Debt/ CFO (x)0.290.320.010.000.01
    AnnualFY 2025FY 2024FY 2023FY 2022FY 2021
    Net Cash flow from Operating Activities1,073.671,135.97367.89791.29604.93
    Net Cash used in Investing Activities1,578.20-2,923.921,208.22-1,010.23-1,524.55
    Net Cash flow from Financing Activities-339.54-7.4014.9234.901,238.46
    Net Cash Flow2,316.42-1,789.011,594.04-180.73322.42
    Closing Cash & Cash Equivalent2,432.62116.211,905.22311.18491.92
    Closing Cash & Cash Equivalent Growth (%)1,993.39-93.90512.25-36.74190.22
    Total Debt/ CFO (x)0.000.000.010.000.01

    All figures in Rs Cr, unless mentioned otherwise

    View Details
  • AnnualFY 2025FY 2024FY 2023FY 2022FY 2021
    Return on Equity (%)7.638.859.8116.9216.88
    Return on Capital Employed (%)11.4312.5013.8922.3922.36
    Return on Assets (%)6.227.248.8915.4615.34
    Interest Coverage Ratio (x)35.3057.38169.90330.81392.33
    Asset Turnover Ratio (x)0.510.580.440.6153.30
    Price to Earnings (x)37.5939.3726.8144.4440.82
    Price to Book (x)2.873.482.637.506.87
    EV/EBITDA (x)16.1519.1713.5429.1926.12
    EBITDA Margin (%)26.3926.5334.9039.4041.49
    AnnualFY 2025FY 2024FY 2023FY 2022FY 2021
    Return on Equity (%)11.1711.599.7516.9316.88
    Return on Capital Employed (%)15.0315.4813.8222.3922.36
    Return on Assets (%)10.4510.938.8415.4715.34
    Interest Coverage Ratio (x)72.59200.87169.82331.03392.34
    Asset Turnover Ratio (x)0.410.460.440.6153.30
    Price to Earnings (x)24.1029.1526.9544.4440.82
    Price to Book (x)2.693.372.637.506.87
    EV/EBITDA (x)14.3618.2413.6129.1926.12
    EBITDA Margin (%)40.2737.8034.8139.4141.49

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime
  • Stock Forecast Non Prime User

    Invest in the Best

    Check two-year estimates on Price, Revenue & Earnings

    READ FOR FREE ON APP
  • Stock Forecast Non Prime User

    Invest in the Best

    Check two-year estimates on Price, Revenue & Earnings

    READ FOR FREE ON APP
  • Stock Forecast Non Prime User

    Invest in the Best

    Check two-year estimates on Price, Revenue & Earnings

    READ FOR FREE ON APP

Technicals

  • No Data Available

  • 41%
    Positive Movement
    since 1st Jan 2005
    on basis
    59%
    Negative Movement
    since 1st Jan 2005
    on basis
    Exclude

    Global Meltdown1st Jan 2008 to 10th Nov 2008

    Covid Crisis1st Feb 2020 to 31st Mar 2020

  • R12323.50Pivot

    2301.30

    		S12261.10
    R22363.70S22238.90
    R32426.10S32176.50
  • 5 Days14 Days28 Days
    80.5884.2277.10

Peer Comparison

Found Peer Comparison useful?

Shareholding Pattern

  • CategoryNo. of SharesPercentage% Change QoQ
    Promoters8,53,93,93451.83 %0.00
    Pledge00.00 %0.00
    FII1,20,23,8007.29 %-0.29
    DII5,49,53,98833.36 %0.39
    MF5,23,54,59231.78 %0.35
    Others1,23,84,7017.52 %-0.10
  • CategoryMar 2026Dec 2025Sep 2025Jun 2025
    Promoters51.8351.8351.8351.83
    Pledge0.000.000.000.00
    FII7.297.587.897.39
    DII33.3632.9632.6232.86
    Mutual Funds31.7831.4230.1930.67
    Others7.527.627.657.92

Mutual Funds Ownership

MF Ownership as on 30 April 2026

View all Mutual Fund Schemes

Gland Pharma Top Searches

    Corporate Actions

    • Board Meeting

      Quarterly Results

      Jan 09, 2026

      Board Meeting

      Quarterly Results

      Oct 17, 2025

      Board Meeting

      Quarterly Results

      Jul 21, 2025

    • Announced onMeeting on
      Jan 09, 2026Jan 28, 2026
      Quarterly Results
      Oct 17, 2025Nov 03, 2025
      Quarterly Results
      Jul 21, 2025Aug 05, 2025
      Quarterly Results
      May 06, 2025May 20, 2025
      Audited Results & Final Dividend
      Jan 16, 2025Feb 03, 2025
      Quarterly Results
    • Announced onEx-DateDividend%
      May 20, 2025Aug 14, 20251800%
      May 22, 2024Aug 16, 20242000%

    • No Data Available

    • No Data Available

    • No Data Available

    • Announced onMeeting on
      May 20, 2025Aug 28, 2025
      -
      Feb 28, 2025Apr 01, 2025
      -
      Feb 07, 2025Mar 11, 2025
      -
      Nov 08, 2024Dec 10, 2024
      -
      May 22, 2024Aug 30, 2024
      -

    About Gland Pharma

    Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 37,363.46 Crore) operating in Pharmaceuticals sector.

    Show More

    Industry

    Pharma - Indian

    Key Indices Listed On

    Nifty Smallcap 100, Nifty 500, BSE 500, Nifty Pharma, Nifty MNC

    Address

    Sy.No. 143-148, 150 & 151,Near Gandi Maisamma �X� Roads,Hyderabad, Telangana - 500043

    Contact

    investors@glandpharma.com

    https://www.glandpharma.com

    Executive Leadership

    SS

    Srinivas Sadu

    Executive Chairman
    SG

    Shyamakant Giri

    Chief Executive Officer
    JA

    Jia Ai (Allen) Zhang

    Non Exe.Non Ind.Director
    WH

    Wei Huang

    Non Exe.Non Ind.Director
    Show More

    Auditors

    Deloitte Haskins & Sells
    S R Batliboi & Associates LLP

    FAQs about Gland Pharma share

    • 1. What's Gland Pharma share price today and what are Gland Pharma share returns ?
      Gland Pharma share price is Rs 2,267.80 as on 10 Jun, 2026, 03:52 PM IST. Gland Pharma share price is down by 0.91% based on previous share price of Rs. 2247.8.
    • 2. What are the returns for Gland Pharma share?
      Return Performance of Gland Pharma Shares:
      • 1 Week: Gland Pharma share price moved up by 1.59%
    • 3. What is 52 week high/low of Gland Pharma share price?
      In last 52 weeks Gland Pharma share had a high price of Rs 2,396.00 and low price of Rs 1,573.60
    • 4. What is the PE & PB ratio of Gland Pharma?
      The PE ratio of Gland Pharma stands at 36.7, while the PB ratio is 3.87.
    • 5. What is the market cap of Gland Pharma?
      Market Capitalization of Gland Pharma stock is Rs 37,363.46 Cr.

    Top Gainers

    As on 03:59 PM | 10 Jun 2026
    Inox India
    1,891.60
    204.90 (12.15%)
    Akums Drugs & Pharma
    592.10
    43.86 (8.00%)
    Chambal Fertilisers
    477.65
    22.90 (5.04%)
    Afcons Infrastru
    330.05
    14.56 (4.62%)
    Concord Biotech Ltd.
    1,330.70
    58.50 (4.60%)

    Top Losers

    As on 03:59 PM | 10 Jun 2026
    Oil India Ltd
    427.35
    -48.60 (-10.22%)
    IFCI
    71.83
    -5.24 (-6.80%)
    Manappuram Finance
    288.25
    -19.00 (-6.19%)
    Jindal Saw
    225.16
    -14.66 (-6.11%)
    NLC India
    309.60
    -18.15 (-5.54%)

    Equity Quick Links

    Top Gainers
    Top Losers
    Hourly gainers
    Hourly losers
    Sensex
    Nifty
    NSE
    BSE
    Midcap stocks
    Smallcap stocks
    Largecap stocks
    Sensex
    Nifty
    NSE
    BSE
    MCX Live

    More from Markets

    IPO
    Stock market news
    Budget 2022 Live Updates
    Cryptocurrency
    Currency converter
    NSE holiday list

    Trending in Markets

    DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

    DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

    By using this site, you agree to the Terms of Service and Privacy Policy.

    Business News › Markets › Stocks › Stock Price Quotes › Gland Pharma Share Price

    Browse Companies

    ABCDEFGHIJKLMNOPQRSTUVWXYZ
    123456789

    Popular Categories

    Hot on Web

    In Case you missed it

    Top Searched Companies

    Copyright © 2026 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights:
    Times Syndication Service

    Do Not Sell My Personal Information